Johnson & Johnson is a holding company, with operating companies conducting business in virtually all countries of the world. The Company’s primary focus is products related to human health and well-being. Johnson & Johnson was incorporated in the State of New Jersey in 1887.
Cash figures as of 2026-09-27. Database snapshot: 2026-11-10.
Cap table as of 2026-06-30.
Pasritamig + JNJ-9401 Phase 1 Positive · 2026-11-08
Pasritamig + JNJ-9401 Phase 1 · prostate cancer, metastatic castration-resistant
Primary: Safety and preliminary clinical activity (PSA response) of pasritamig in combination with JNJ-9401 at the recommended regimen in metastatic castration-resistant prostate cancer (Phase 1 study NCT06095089) — 73% (11 of 15 patients) achieved reductions of at least 50 percent in prostate-specific antigen (PSA50) at the recommended regimen
· 47% (7 of 15 patients) achieved PSA reductions of at least 90 percent (PSA90)
· Four patients achieved undetectable PSA levels
· All seven patients who achieved PSA reductions of at least 90 percent remained on treatment for more than six months without disease progression
· 144 patients had enrolled in the study as of June 15, 2026; patients at the recommended regimen had a median of four prior lines of systemic therapy
· Recommended regimen: JNJ-9401 200 mg subcutaneously every six weeks + pasritamig 300 mg intravenously every six weeks, following two initial weekly pasritamig step-up doses
· Combination is being evaluated in the Phase 3 KLK2-comPAS study (NCT07164443) in mCRPC
Safety: At the recommended regimen, no Grade 3 or higher treatment-related adverse events, no dose-limiting toxicities, and no treatment-related adverse events leading to discontinuation or death; cytokine release syndrome in three patients (20%), all Grade 1, none requiring tocilizumab; no ICANS
Tocilizumab Phase 1 Negative · 2026-11-08
JNJ-9401
Primary: Safety and determination of the recommended regimen (Phase 1 Part 1 primary objectives); preliminary clinical activity measured by PSA response — 73 percent (11 of 15 patients) achieved reductions of at least 50 percent in prostate-specific antigen (PSA) at the recommended regimen, including 47 percent (7 of 15 patients) who achieved reductions of at least 90 percent
· 144 patients had enrolled in the study as of June 15, 2026
· Patients treated at the recommended regimen had received a median of four prior lines of systemic therapy (range, two to six)
· Four patients achieved undetectable PSA levels
· All seven patients who achieved PSA reductions of at least 90 percent remained on treatment for more than six months without disease progression
· Recommended regimen: JNJ-9401 200 mg administered subcutaneously every six weeks in combination with pasritamig 300 mg administered intravenously every six weeks, following two initial weekly pasritamig step-up doses
· The combination is being evaluated in the Phase 3 KLK2-comPAS study (NCT07164443)
Safety: No Grade 3 or higher treatment-related adverse events, dose-limiting toxicities, or treatment-related adverse events leading to discontinuation or death were reported at the recommended regimen; cytokine release syndrome was observed in three patients (20 percent), all Grade 1, and no cases of ICANS were reported
Icotrokinra Phase 3 Positive · 2026-11-07
IL-23 · arthritis, psoriatic
Primary: American College of Rheumatology 20 (ACR20) response at Week 16 — 58% of patients achieving an American College of Rheumatology 20 (ACR20) response compared with 41% receiving placebo at Week 16
· ACR50 at Week 16: 29% vs. 16% placebo
· ACR70 at Week 16: 13% vs. 5% placebo
· IGA 0/1 (clear or almost clear skin) at Week 16: 57% vs. 14% placebo (nominal p<0.001)
· PASI 90 at Week 16: 37% vs. 6% placebo (nominal p<0.001)
· Week 24: ACR20 69%, ACR50 40%, ACR70 18%
· Week 24 among patients with qualifying baseline skin involvement: IGA 0/1 64%, PASI 90 56%
Safety: Safety data through Week 24 were consistent with the established safety profile of ICOTYDE, with no new safety signals identified
Ustekinumab Phase 3 Positive · 2026-11-06
ICONIC-ASCEND
Guselkumab Phase 3 Positive · 2026-10-19
GALAXI / FUZION
Primary: Long-term maintenance efficacy in Crohn's disease: Week 144 (GALAXI long-term extension) clinical remission (CDAI <150) and endoscopic remission, and Week 48 (FUZION) combined fistula remission in Crohn's disease with perianal fistula — GALAXI Week 144 as-observed: clinical remission 94% (172/183) on guselkumab 100 mg q8w and 91% (185/204) on 200 mg q4w; endoscopic remission 52% (89/172) and 61% (119/195). FUZION Week 48 combined fistula remission: 35% in the 100 mg q8w group (up from 28% at Week 24) and 26% in the 200 mg q4w group (27% at Week 24)
· 90-day corticosteroid-free clinical remission at Week 144: 89% (162/183) on 100 mg q8w and 88% (179/204) on 200 mg q4w
· 74% (432/582) of guselkumab-treated GALAXI patients remained on treatment through three years (Week 144)
· FUZION: 90% of randomised patients, bio-naive and bio-experienced, completed treatment through Week 48
· FUZION randomised patients: n=113 (100 mg q8w maintenance) and n=115 (200 mg q4w maintenance), after 200 mg IV induction at Weeks 0, 4, 8
Safety: Safety findings through Week 144 (GALAXI) and Week 48 (FUZION) were consistent with the known safety profile of guselkumab in Crohn's disease; common adverse reactions include respiratory tract infections, diarrhoea, and injection site reactions